wast
nasopharyng
swab
n
evalu
reversetranscriptas
polymeras
chain
reactionelectrospray
ioniz
mass
spectrometri
plexid
broad
respiratori
viru
surveil
kit
version
compar
direct
fluoresc
antibodi
xtag
respiratori
viru
panel
percent
agreement
sensit
specif
sensit
specif
respect
sensit
viru
except
parainfluenza
specif
respiratori
virus
especi
influenza
viru
season
sourc
morbid
mortal
unit
state
global
mahoni
mahoni
et
al
swayn
spackman
influenza
pandem
illustr
import
diagnost
detect
identifi
respiratori
virus
gener
accur
diagnost
import
infecti
diseas
manag
make
treatment
decis
novel
pathogen
discoveri
mahoni
mahoni
et
al
swayn
spackman
viral
diagnost
migrat
cultur
rapid
molecular
methodolog
laboratori
util
method
mahoni
mahoni
et
al
respiratori
viru
diagnost
cultur
immunolog
techniqu
sequenc
molecular
diagnost
advantag
disadvantag
cultur
low
complex
also
low
sensit
requir
viabl
organ
immunolog
techniqu
like
direct
fluoresc
antibodi
dfa
rapid
labori
lower
sensit
molecular
diagnost
sequenc
provid
substanti
inform
technic
complex
impract
molecular
diagnost
although
fairli
complex
becom
prefer
technolog
high
sensit
shorter
test
time
reversetranscriptas
polymeras
chain
reactionelectrospray
ioniz
mass
spectrometri
rtpcresim
technolog
highli
complex
technolog
provid
accur
diagnost
inform
respiratori
virus
particularli
influenza
chen
et
al
chen
et
al
deyd
et
al
deyd
et
al
forman
et
al
jeng
et
al
sampath
et
al
tang
et
al
murillo
et
al
perform
evalu
rtpcresim
respiratori
viru
detect
perform
notabl
chen
et
al
chen
et
al
forman
et
al
tang
et
al
expand
studi
util
retrospect
collect
wast
nasopharyng
swab
np
compar
plexid
rtpcresim
rv
kit
abbott
molecular
de
plain
il
usa
result
combin
dfa
xtag
respiratori
viru
panel
xtag
rvp
luminex
corpor
austin
tx
usa
result
well
dfa
xtag
rvp
individu
determin
percent
agreement
sensit
specif
kappa
rv
part
institut
review
boardapprov
studi
wast
np
test
result
dfa
xtag
rvp
collect
clinic
virolog
sampl
select
posit
neg
test
result
ratio
n
posit
n
neg
n
sampl
initi
test
dfa
total
n
posit
n
neg
n
dfa
neg
sampl
test
xtag
rvp
patient
immunocompromis
xtag
rvp
screen
immunocompromis
patient
yield
addit
posit
sampl
n
comparison
rtpcr
esim
remain
sampl
n
neg
either
dfa
nonimmunocompromis
individu
neg
dfa
xtag
rvp
immunocompromis
individu
nucleic
acid
extract
perform
util
arrow
nordiag
oslo
norway
per
manufactur
instruct
broad
respiratori
viru
surveil
kit
version
rv
plexid
util
amplif
analysi
per
manufactur
instruct
posit
reaction
defin
respiratori
viru
identif
q
score
result
compar
report
diagnost
result
either
dfa
xtag
rvp
determin
percent
agreement
sensit
specif
kappa
posit
sampl
type
consid
neg
specif
purpos
virus
ie
sampl
respiratori
syncyti
viru
rsv
posit
influenza
ab
neg
consid
neg
calcul
influenza
specif
discord
test
perform
due
sampl
nucleic
acid
extract
volum
limit
posit
sampl
consist
influenza
n
influenza
influenza
b
rsv
n
coronaviru
n
metapneumoviru
n
parainfluenza
viru
n
adenoviru
n
test
posit
percent
agreement
dfa
xtag
rvp
respect
result
posit
percent
agreement
specif
viru
summar
tabl
dfa
xtag
rvp
also
util
gold
standard
calcul
sensit
specif
overal
viru
rv
tabl
rv
result
compar
well
dfa
xtag
rvp
overal
agreement
kappa
confid
interv
ci
overal
posit
neg
agreement
dfa
xtag
rvp
util
gold
standard
assay
sensit
specif
rtpcresim
compar
dfa
xtag
rvp
viru
percent
agreement
sensit
specif
howev
parainfluenza
viru
overal
agreement
sensit
limit
number
parainfluenza
posit
n
evalu
contribut
appear
sampl
qualiti
volum
issu
case
result
would
affect
across
posit
sampl
parainfluenza
fals
neg
well
falseneg
result
studi
potenti
quantiti
viru
sampl
test
limit
detect
copi
per
well
virus
rv
primer
amplifi
chen
et
al
result
similar
chen
et
al
chen
et
al
forman
et
al
chen
et
al
util
rv
forman
et
al
evalu
employ
rv
sensit
specif
improv
respect
respect
compar
chen
et
al
posit
percent
agreement
improv
compar
chen
et
al
studi
report
higher
agreement
metapneumoviru
forman
et
al
although
studi
evalu
fewer
metapneumoviru
posit
n
nucleic
acid
extract
methodolog
util
differ
studi
chen
et
al
chen
et
al
forman
et
al
possibl
contribut
sensit
specif
improv
despit
numer
limit
studi
result
present
add
addit
perform
characterist
inform
previous
publish
studi
util
rtpcresim
detect
identif
respiratori
virus
deyd
et
al
deyd
et
al
sampath
et
al
tang
et
al
murillo
et
al
sampl
posit
coronaviru
metapneumoviru
adenoviru
test
analysi
perform
discrep
result
due
low
sampl
nucleic
acid
extract
volum
rtpcresim
test
complet
especi
case
dfanegativertpcresimsposit
sampl
tabl
comparison
dfa
rtpcresim
problemat
comparison
nonamplifi
diagnost
dfa
amplifi
diagnost
rtpcresim
may
skew
rtpcresim
perform
characterist
addit
xtag
rvpposit
result
initi
dfa
neg
discrep
also
problemat
addit
dfa
could
gener
falseposit
result
dfaposit
detect
confirm
rtpcresim
xtag
rvp
accur
comparison
would
util
amplifi
test
xtag
rvp
type
specif
realtim
pcr
although
dfa
comparison
suboptim
best
avail
comparison
method
base
clinic
virolog
screen
algorithm
use
report
respiratori
viru
diagnos
final
xtag
rvp
assay
perform
dfaneg
sampl
collect
among
immunocompromis
patient
neg
per
clinic
virolog
test
algorithm
polici
mani
dfaneg
sampl
collect
among
immunocompet
patient
could
test
posit
xtag
rvp
addit
dfa
neg
rtpcresim
fals
posit
tabl
could
accur
confirm
rtpcresim
xtag
rvp
directli
compar
sampl
rtpcresim
technolog
demonstr
capabl
detect
identifi
respiratori
virus
compar
dfa
xtag
rvp
util
screen
np
sampl
respiratori
virus
base
limit
associ
studi
evalu
rtpcresim
technolog
includ
prospect
analysi
comparison
multipl
molecular
method
requir
clinic
implement
chen
kf
rothman
ramachandran
p
blyn
l
sampath
r
ecker
dj
et
al
rapid
identif
virus
nasal
pharyng
aspir
acut
viral
respiratori
